fda shortage semaglutide injection resolved feb 21 2025 End of Means Big Changes for Prescribers and Compounders FDA: Ozempic and Wegovy drug

Similar to managing high blood pressure or cholesterol, GLP-1 medications are often part of a lifelong approach to care for chronic conditions, as discussed in long-term therapy research

Skip if you have active gastroparesis or any serious GI motility issue

Jump to your state's requirements Semaglutide is approved for weight management in adults with a BMI over 30

H., Pagotto, U.,

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for type 2 diabetes management (under the brand name Ozempic), chronic weight management (Wegovy), and cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight